Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Skeletal disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Disorders of the skeletal system; includes both bone and cartilage.
Implant for treating ailments of a joint or a bone
InactiveUS6436146B1Increase coefficient of frictionImprove stabilityFinger jointsWrist jointsDiseasePyrolytic carbon
The implant has at least one contact surface portion, made of pyrolytic carbon, designed to be in mobile contact with at least one bony surface when the implant is implanted in a patient. Furthermore, the implant is free from any attaching means, so that it remains free with respect to the at least one bony surface when implanted in the patient.
Owner:TORNIER SA SAINT ISMIER
Active variants of FGF with improved specificity
InactiveUS7288406B2Enhanced receptor specificityImprove in vivo activitySugar derivativesPeptide/protein ingredientsDiseaseReceptor subtype
The present invention provides active fibroblast growth factor variants demonstrating enhanced receptor subtype specificity. The preferred novel variants retain binding to FGF Receptor Type 3 (FGFR3) triggering intracellular downstream mechanisms leading to activation of a biological response. Methods of utilizing preferred FGF mutants in preparation of medicaments for the treatment of malignancies and skeletal disorders including osteoporosis and enhancing fracture healing and wound healing processes are provided.
Owner:PROCHON BIOTECH
Inhibitors of the bmp signaling pathway
The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and / or proliferation.
Owner:THE GENERAL HOSPITAL CORP +1
FGF variants and methods for use thereof
ActiveUS7563769B2High activityHigh affinityPeptide/protein ingredientsSkeletal disorderDiseaseReceptor subtype
The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and / or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
Owner:PROCHON BIOTECH
Use of S,S-Reboxetine in the Treatment of Pain
InactiveUS20080261984A1Efficacious in treating painOrganic active ingredientsNervous disorderDiseaseVisceral pain
Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains / sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed.
Owner:PFIZER INC
Identification of a micro-rna that activates expression of beta-myosin heavy chain
InactiveUS20090180957A1Decrease mortality and morbidityImprovement of symptomBiocideOrganic active ingredientsMusculoskeletal impairmentEccentric hypertrophy
The present invention relates to the identification of a microRNA, miR-208, that induces the expression of β-myosin heavy chain (β-MHC) and represses fast skeletal muscle contractile protein genes. Inhibition of this function is proposed as a treatment for cardiac fibrosis, hypertrophy and / or heart failure, and augmentation of this function can be used to repress slow fiber genes and activate fast fiber genes in the treatment of musculoskeletal disorders.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
InactiveUS20060275503A1Reduce morbidityIncrease bone densityHeavy metal active ingredientsBiocideSkeletal disorderIncreased Bone Density
A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and / or increasing bone density and / or improving healing of fractured bone and / or improving bone quality are administered for use in the treatment and / or prophylaxis of cartilage and / or bone conditions.
Owner:OSTEOLOGIX AS
Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists
This invention relates to the use of EP2 receptor subtype selective prostaglandin E2 agonists to augment bone mass including the prevention and treatment of skeletal disorders in mammals, including humans.
Owner:PFIZER INC
FGF variants and methods for use thereof
ActiveUS20050148511A1High affinityImprove biological activityPeptide/protein ingredientsSkeletal disorderDiseaseReceptor subtype
The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and / or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
Owner:PROCHON BIOTECH
Indazolinone compositions useful as kinase inhibitors
The present invention provides compounds of formula I:These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.
Owner:VERTEX PHARMA INC
Prostaglandin agonists
InactiveUS20030078261A1Reduce the chance of fractureIncrease bone formationBiocideSenses disorderAgonistOsteoporosis
Owner:PFIZER INC
Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
InactiveUS20120258917A1Inhibit cell proliferationExcellent tumor regressionSenses disorderNervous disorderDiseaseSide effect
Owner:STRYKER CORP
Method of Neuromusculoskeletal Proprioceptive Re-education and Development of a Living Body and Apparatus Therefor
InactiveUS20080255477A1Effective treatmentEnhance proprioceptionPerson identificationChiropractic devicesBiological bodyDisease
In combination, vertically percussive vibration and non-symmetrical forces are applied to a patient. The non-symmetrical forces may be generated by a variety of unevenly applied weights that are supported at appropriate body locations in a manner that upsets normal body load symmetry. The non-symmetrical forces in combination with vertically percussive vibrations induce neuromusculoskeletal proprioceptive re-education and development within a living body to correct musculo-skeletal disorders including but not limited to scoliosis. A special posture modifying chair and head-orienting glasses may be used instead of or in addition to unevenly applied weights. An additional force concentrating treatment apparatus is also presented.
Owner:WOGGON DENNIS A +3
Synergistic herbal composition for treatment of rheumatic and musculo-skeletal disorders (RMSDS)
InactiveUS20120021077A1Reduce denaturationReduce releaseBiocideAntipyreticHerbal preparationsDisease
The present invention deals with a synergistic herbal composition useful for treatment of rheumatic and musculo-skeletal disorders (RMSDs) comprising a base formulation (50-60%) and plant parts and / or extracts of the plant (40-50%) selected from the group consisting of Withania somnifera, Tribulus terrestris, Phyllanthus emblica and Boswellia serrata optionally along with pharmaceutically acceptable excipients. The herbal formulation is capable of causing simultaneous long term decrease in glycosaminoglycan (GAG) release and aggrecan by cartilage explants resulting in reduction of pain, inflammation, stiffness and low degeneration of bones, joints, muscles and other connective tissues. The present invention further deals with a process for the preparation of the said herbal formulation and a method of treating RMSDs using the formulation up to a high safety level and stable for a long durations.
Owner:COUNCIL OF SCI & IND RES
Mineral trioxide aggregate (MTA) composition and use
ActiveUS8722100B2Good effectImprove mechanical propertiesHeavy metal active ingredientsBiocideHigh fluoridePhosphate
The present application discloses a fast-setting mineral trioxide aggregate (MTA) with fluoride release for practical treatment of diseases in teeth and bone, e.g. for caries treatment and / or prevention. The cariostatic MTA contain calcia-silica-alumina cement with moderately increased tricalcium aluminate content allowing high calcium hydroxide release. The MTA composition support remineralization and biomineralization, and it is suitable for stimulation of hard tissue regeneration. MTA embodiments contain superplasticizer and nanosilicate for improved mechanical properties. The MTA compositions include optional radiocontrast and nano-enriched leachable fluorine, nitrate, strontium, and phosphate. The fast-setting MTA paste exhibits flow-to-clay-like consistency, which allows new practical applications including cavity lining, temporary restoration, bonding, and cementations in one MTA embodiment. The high calcium hydroxide and high fluoride release are suitable for caries prevention and treatment, and per se inhibition of dental symptoms.
Owner:DENTOSOLVE APS
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
ActiveUS10004814B2Reduce expressionEnhancing muscle mass and functionOrganic active ingredientsGenetic material ingredientsDiseaseWhole body
Owner:SIRNA THERAPEUTICS INC
Use of reboxetine for the treatment of pain
InactiveCN101208095AImprove mental actionOrganic active ingredientsNervous disorderVisceral painTreatment pain
Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains / sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed.
Owner:PFIZER INC
Medicament for treating muscle and skeletal diseases
The present invention concerns the field of therapy of muscle, joint and / or skeletal diseases. In particular, the invention relates to a composition comprising a first solution comprising preparations of Aconitum napellus, Arnica montana, radix, Bellis perennis, Belladonna, Calendula officinalis, Chamomilla, Echinacea, Echinacea purpurea, Hamamelis virginiana, Hepar sulfuris calcareum, Hypericum perforatum, Mercuris solubilis, Millefolium, and Symphytum officinale, and a second solution comprising preparations of Arnica montana, radix, Dulcamara, Rhus toxicodendron, Sanguinaria Canadensis, and Sulphur. Further provided is a method of treating and / or preventing the progression of a disease comprising administering to a subject in need of a treatment a therapeutically effective amount of the said composition or said first and said second solution. The invention also contemplates a kit comprising said first and said second solution.
Owner:BIOLOGISCHE HEILMITTEL HEEL
Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
This invention relates, e.g., to a synthetic compound, Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders.
Owner:RGT UNIV OF CALIFORNIA
Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders
An isolated polypeptide is provided, comprising an amino acid sequence being at least 88% homologous to SEQ ID NO: 15 as determined by BlastP using default parameters, the isolated polypeptide being capable of promoting cell adhesion and / or cell homing.
Owner:RAMOT AT TEL AVIV UNIV LTD
Soluble fgfr3 decoys for treating skeletal growth disorders
InactiveUS20180148494A1Easy genetic manipulationReduce contentPeptide/protein ingredientsAntibody mimetics/scaffoldsChemistryAggrecan
The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
Owner:UNIV COTE DAZUR +3
SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (siNA) CONJUGATED TO A LIPOPHILIC MOIETY
ActiveUS20160256570A1Reduce expressionImprove muscle massOrganic active ingredientsGenetic material ingredientsDiseaseCholesterol
The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and / or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and / or diseases or disorders that result in conditions in which muscle is adversely affected.
Owner:SIRNA THERAPEUTICS INC
Soluble fgfr3 decoys for treating skeletal growth disorders
PendingUS20210009657A1Easy genetic manipulationReduce contentPeptide/protein ingredientsAntibody mimetics/scaffoldsHeterologousDisease
Owner:THERACHON HLDG GMBH +3
Method for treating muscular tendonous hypertonicity
InactiveUS20090227916A1Improve performanceRelieve stressGenitals massageSuction-kneading massageMuscle tissueMuscle spindle
A method of manual therapy used in the correction of musculo-skeletal dysfunction in the fields of medicine, athletics, and entertainment that uses ligamentous tissue to influence musculo-tendonous hypertonicity, correction of numerous muscular and skeletal pathologies can be made. The method uses the influence of light tactile pressure to ligament receptors to regulate and reprogram muscular stiffness much in the same way activity in primary muscle spindle afferents, modify muscle tonicity The steps are as follows: location of e the symptomatic anatomy, targeted muscle or muscles are shortened to relax muscle-spindle fibers, application of light to mild static tactile engagement of the corresponding ligament found by use of pre-determined referral patterns then held for 15-30 seconds or until the muscle tissue has released it's tension, muscle lengthening and re-assessment. The last two steps are repeated until 80-95% reduction in abnormal muscle tension trigger-points is met.
Owner:GOHL ARIK WARREN
Body-strengthening and body-building food composition and preparation method thereof
PendingCN109170916ASmall molecular weightPromote absorptionLipidic food ingredientsNatural extract food ingredientsDiseaseJoints inflammation
The present invention provides a body-strengthening and body-building food composition and a preparation method thereof. The composition comprises the following components in parts by weight: 0.001-0.3 part of casein phosphopeptide, 0.05-3 parts of deep sea fish collagen peptides, 0.01-2 parts of yak bone powder, 0.005-1 part of colostrum basic protein, 0.01-2 parts of hydrolyzed egg yolk powder and 0.001-0.2 part of krill oil powder. The body-strengthening and body-building food composition can be used for preparing health-care food. The health-care food composition can prevent and relieve bone and joint inflammation, osteoporosis and other skeletal diseases, at the same time has effects on delaying aging, preventing geriatric diseases, strengthening body and building body, etc., and is suitable for a long-term consumption.
Owner:丽睿客信息科技(北京)有限公司
Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
InactiveUS20100143473A1Treatment and/or prophylaxis of a cartilage and/or bone diseaseReduce morbidityHeavy metal active ingredientsBiocideSkeletal disorderIncreased Bone Density
A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and / or increasing bone density and / or improving healing of fractured bone and / or improving bone quality are administered for use in the treatment and / or prophylaxis of cartilage and / or bone conditions.
Owner:OSTEOLOGIX AS
Compositions and methods for minimally-invasive systemic delivery of proteins including tgf-beta superfamily members
InactiveUS20140342976A1Minimizes and avoids leakageInhibit cell proliferationSenses disorderNervous disorderDiseaseSide effect
The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.
Owner:MARIEL THERAPEUTICS
Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
InactiveUS20100204123A1Inhibit tumor cell proliferationExcellent tumor regressionSenses disorderNervous disorderDiseaseSide effect
The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.
Owner:STRYKER CORP
Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders
An isolated polypeptide is provided, comprising an amino acid sequence being at least 88% homologous to SEQ ID NO: 15 (human) as determined by BlastP using default parameters, the isolated polypeptide being capable of promoting cell adhesion and / or cell homing.
Owner:RAMOT AT TEL AVIV UNIV LTD
Spinopelvic fixation technology
ActiveUS10596004B2Precise alignmentAdditive manufacturing apparatusInternal osteosythesisSpinal columnPelvic region
Systems and methods for treating musculo skeletal disorders of the spinopelvic anatomy including treating spinal deformities by spinopelvic fixation including fusion of the sacroiliac joint at the base of long spinal fusion construct cases. The system may include implants designed to be used as an adjunct to long spinal fusions to further the immobilization and stabilization of the sacroiliac joint. The implants may be designed to augment an S2AI screw and an S1 screw in order to improve durability of the foundation of the spinal construct. The implants may have a triangular cross section.
Owner:JCBD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com